40 Participants Needed

Oral Cavity Reconstruction for Oral Cancer

MC
Overseen ByMedical College of Wisconsin Cancer Center Clinical Trials Office
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Medical College of Wisconsin
Must be taking: Ampicillin/sulbactam
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to understand why infections sometimes occur after surgery to rebuild parts of the mouth affected by cancer. Researchers seek to observe how bacteria and antibiotics interact during these procedures to uncover potential causes of these infections. This study targets individuals who have had oral or throat cancer and plan to undergo surgery involving mouth reconstruction with tissue flaps. Participants must use a specific antibiotic, ampicillin/sulbactam, as part of their treatment plan. As an unphased trial, this study allows participants to contribute to important research that could improve surgical outcomes for future patients.

Do I need to stop taking my current medications for the trial?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that oral cavity reconstruction is safe?

Research has shown that rebuilding the mouth after oral cancer surgery can sometimes lead to problems. One study found that the wound reopened in 10% of cases, and infections occurred in about 9% of cases. These findings suggest that while the procedure is generally safe, some risks exist.

Doctors have performed these surgeries for a long time, so they understand the risks and how to manage them. If concerns arise, discussing them with a doctor can help clarify how these numbers might relate to an individual case.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to uncover the reasons why surgical site infections occur after oral cancer surgeries. Unlike standard treatments that focus solely on infection management, this study seeks to understand the underlying mechanisms causing these infections. By identifying these mechanisms, the trial could lead to new preventative strategies, making surgeries safer and reducing recovery time for patients.

What evidence suggests that oral cavity reconstruction is effective for preventing surgical site infections?

Studies have shown that rebuilding the mouth area can lead to positive results for patients. One study found that 62.5% of patients experienced excellent improvements in function after 12 months, while another 15% showed good improvements. This demonstrates the effectiveness of these surgeries in restoring function. Additionally, research has found that the implants used after these surgeries have a long lifespan, with a success rate of up to 92.5%. These findings suggest that oral cavity reconstruction, which participants in this trial will undergo, effectively improves both function and quality of life for patients after oral cancer surgery.14678

Who Is on the Research Team?

JZ

Joseph Zenga, MD

Principal Investigator

Medical College of Wisconsin

Are You a Good Fit for This Trial?

Inclusion Criteria

I am willing and able to follow the study rules and attend all appointments.
I am 21 years old or older.
I am scheduled for oral surgery with a specific antibiotic planned for prevention.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Surgery and Sample Collection

Participants undergo standard of care oral cavity reconstruction surgery with biospecimen collection

1 day
1 visit (in-person)

Post-operative Monitoring

Participants are monitored for surgical site infections and antibiotic concentrations are measured

Up to 30 days

Follow-up

Participants are monitored for safety and effectiveness after surgery

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Oral Cavity Reconstruction

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Subjects undergoing Oral Cavity ReconstructionExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Medical College of Wisconsin

Lead Sponsor

Trials
645
Recruited
1,180,000+

National Institute of Dental and Craniofacial Research (NIDCR)

Collaborator

Trials
312
Recruited
853,000+

Citations

Functional Outcomes and Quality of Life Following ...

At 12 months, 62.5% of our patients achieved excellent functional outcomes, and 15.0% achieved good outcomes, underscoring the efficacy of SCF ...

Retrospective analysis on prognosis of oral cancer patients ...

This study analyzed postoperative outcomes such as complications, recurrence rate, and survival rate by these two approaches.

Clinical and oncological outcome in locoregional ...

The 3-year overall survival was 31,4% with advanced tumor stage and reduced clinical performance score at the start of treatment being independently associated.

Efficacy of Oral Rehabilitation Techniques in Patients With ...

The survival rate was 92.5% for implants placed after ablative surgery and 89.5% for those placed after oncological treatment. The difference in ...

Oncologic outcomes following neoadjuvant ...

The addition of adjuvant chemotherapy to RT was associated with a 5% reduction in the risk of mortality (95% CI: 1%-14%), the protective effect ...

Incidence of flap-related complications in the oral ...

Subgroup analysis of complications indicated that the most common complications were wound dehiscence (10%), infections (9%), total/partial flap ...

Reconstruction in early squamous cell carcinoma of the ...

Estimated 5-year overall and progression-free survival was 85 % and 77 % respectively with no significant difference between stage I or II cancer patients.

Reconstruction in oral malignancy: Factors affecting morbidity ...

87.4% cases were newly diagnosed carcinoma oral cavity. Surgery was the most common upfront treatment modality with seven cases accounting for 6.3% cases.